Spero Therapeutics (SPRO) Assets Average (2017 - 2026)

Spero Therapeutics (SPRO) has 10 years of Assets Average data on file, last reported at $64.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 32.04% year-over-year to $64.0 million; the trailing twelve-month figure through Mar 2026 stood at $64.0 million (down 32.04% YoY), and the FY2025 full-year result was $89.7 million, down 38.74% from the prior year.
• Assets Average for Q1 2026 stood at $64.0 million, up from $61.5 million in the prior quarter.
• Across five years, Assets Average topped out at $175.0 million in Q1 2024 and bottomed at $58.1 million in Q3 2025.
• The 5-year median for Assets Average is $104.7 million (2022), against an average of $108.3 million.
• The widest annual swing landed in 2023, when Assets Average surged 60.8%; it then slumped 59.2% in 2025.
• A 5-year view of Assets Average shows it stood at $94.6 million in 2022, then surged by 52.94% to $144.7 million in 2023, then decreased by 15.13% to $122.9 million in 2024, then plunged by 49.9% to $61.5 million in 2025, then climbed by 3.94% to $64.0 million in 2026.
• The last three Assets Average figures came in at $64.0 million (Q1 2026), $61.5 million (Q4 2025), and $58.1 million (Q3 2025), per Business Quant data.

Peer Comparison